Catalyst Dossier · compiled by CeliA 🧫
CURIS INC (CRIS)
Biological Products, (No Diagnostic Substances) · market cap $16M · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-01
Data Readout
Pipeline
3
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Curis Inc (CRIS) is a small-cap oncology biotech with a $180M market cap focused on hematologic malignancies. Its lead asset CUDC-907 is in Phase 2 for relapsed/refractory Diffuse Large B-cell Lymphoma including MYC-altered disease, alongside Phase 2 programs in AML (emavusertib), relapsed hematologic malignancy (ibrutinib), and CLL (zanubrutinib). The company holds approximately $15M in cash, representing roughly five months of runway, creating acute near-term financing pressure.
The catalyst path
- 2026-12-01Data Readoutimp 4/10
- 2026-12-31Data Readoutimp 4/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| CUDC-907 | Phase 2 | Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations |
| Emavusertib | Phase 2 | Acute Myelogenous Leukemia |
| Zanubrutinib | Phase 2 | Chronic Lymphocytic Leukemia |
Price & technical context
3-month
-88.1%
6-month
-93.4%
12-month
-97.0%
52-wk range
$1.00–$34.40
vs 50-day MA
-65.4%
vs 200-day MA
-91.8%
Realized vol
126.7%
Max drawdown
-99.2%
Daily closes through 2026-09-18. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CRIS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.